Background: SARS-CoV-2, is followed by several manifestations, such as fever, cough, respiratory distress syndrome and mucocutaneous lesions such as papules, urticaria, vasculitic purpura and erythema multiform. Case: A 22-year old woman was diagnosed with COVID-19. Considering the skin and oral lesions, erythema multiform was suggested as the most likely diagnosis. Oral valaciclovir was administered. Discussion: Erythema multiforme were reported in some patients with COVID-19. Its pathophysiology is not yet completely understood, but it seems there is a lymphocyte-mediated hypersensitivity reaction to SARS-CoV-2 antigens presenting in the skin. Conclusion: Mucocutaneous and oral lesions might be the first manifestations of COVID-19. Therefore, during the pandemic, it is prudent to consider this virus as a differential diagnosis once we encounter oral ulceration. Lay abstract We reported a 22-year old woman admitted to the hospital complaining of fever, abdominal pain, nausea and occasional vomiting that started about a week prior. According to the CT scan and real-time reverse transcription polymerase chain reaction (rRT-PCR), the patient was diagnosed with COVID-19. Oral examination by an oral medicine specialist revealed extensive ulcers in the mouth and crusts on the lips and she was diagnosed with erythema multiform. Oral valaciclovir was prescribed for 5 days and oral lesions relatively disappeared after 6 days. The pathophysiology of lesions is not yet completely understood, but it seems there is a hypersensitivity reaction to SARS-CoV-2 antigens presenting in the skin. SARS-CoV-2 could travel to other tissues such as skin, and make alterations to the cutaneous immune system, resulting in various manifestations on the skin.
Introduction: Osteopontin (OPN) is recognized as a potent biomarker of Oral lichen planus (OLP) because of vital role in inflammation and repair process. The aim of present study is assessment of OPN in OLP in comparison with healthy controls (HC). Material and Methods: To explore salivary levels of OPN, a group of 20 subjects with OLP were compared with 20 HC. Salivary OPN levels was measured by enzyme-linked immunosorbent (ELISA) assay. Results: Results indicated elevated OPN levels in lesion size < 1 cm compared with 1 - 3 cm lesion size of OLP (p= 0.02). In contrast, we did not find a significant difference in OPN expression level in saliva from OLP patients and healthy controls (P = 0.96). Discussion: The above results suggest that maybe OPN may serve as a potential biomarker for the monitoring of repair process in OLP.